CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, Inc., a leading AI-driven health technology company and portfolio company of nference, announced today it has received the 2024 MedTech Breakthrough Award ...

Following its successful contribution to the American Association of Equine Practitioners-led project focused on locomotion ...

Clinicians rely daily on electrocardiograms (ECG) to detect common cardiovascular conditions, but accurate diagnoses require high levels of expertise. In a new study that reviewed nearly 1 million ...

A new clinical study shows that PulseAI’s deep learning AI demonstrates superiority over the Apple Watch ECG in the detection of atrial fibrillation. Results have been accepted for presentation at the ...

Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden death in adolescents and initial detection is often difficult. A new UC San Francisco study finds that Artificial Intelligence-enhanced ...

An artificial intelligence (AI) deep-learning algorithm interpreting preoperative ECGs can identify risk for postoperative death in those undergoing cardiac surgery, noncardiac surgery, and ...

CAMBRIDGE, Mass., April 08, 2026--(BUSINESS WIRE)--Anumana, Inc., a leader in cardiovascular AI, today announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI™ algorithm for cardiac ...

Rhythm (Nasdaq:IRTC) today announced findings from two real-world analyses supporting its long-term heart monitoring ...

Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an AI-enabled software-as-a-medical-device ...

Anumana’s innovative AI algorithms recognized for their transformative potential in cardiology - the first of which is now commercially available “At Anumana, we are committed to developing ...